Dr. Santiago Munne — Founder, Reprogenetics

Embryos with an abnormal number of chromosomes do not implant, they miscarry or can cause serious defects in the babies. The older the woman, the more embryos have chromosome abnormalities, thus the decrease in fertility with advancing maternal age.


Twenty years ago we were able for the first time to assess in single cells, biopsied from embryos, their chromosome competence. Thus we presented the hypothesis that selecting normal embryos would improve pregnancy outcomes.


At the time, Preimplantation Genetic Screening (PGS) could analyze only 5 of the chromosomes. It has taken 20 years to demonstrate that with the right technology (all chromosomes analyzed, redundantly), and at the right development stage of the embryo (blastocyst biopsy), implantation rates can double by selecting normal embryos. And if a normal embryo is detected it has the same chance of implanting irrespective of the mother age.


During this meeting we will review the accomplishments of the last 20 years in PGS, and the current lines of new research, while featuring key research leaders developing the tests of tomorrow.

Share via email
Posted in Our Experts
Media Partners

Community Partners

In-Kind Sponsors

Sign up for FP Updates
Family Sponsors

Parent Sponsors

Sibling Sponsors

Friend Sponsors


Digital Cousin Sponsors

Innovation Space Sponsors